Dr. Montgomery is founder and CEO of Seattle-based Cardeas Pharma. He has more than 25 years of life science operations and financing experience, including positions at Genentech, Pathogenesis, Corus Pharma, and Gilead Sciences. Dr. Montgomery has raised over 250 million dollars in venture and public financings. Prior to founding Cardeas, Dr. Montgomery served 4 years as Senior Vice President of Gilead Sciences, and 6 years as Chief Executive Officer of Corus Pharma, a biotechnology company he founded, and which was acquired by Gilead in 2006. Dr. Montgomery also served as Executive Vice President of R&D at PathoGenesis Corporation until its acquisition by Chiron in 2000.
In 1998 the FDA Commissioner recognized Dr. Montgomery with a special citation for leadership in the development and approval of TOBI. For this work, Dr. Montgomery also received the 2009 Inventor of the Year award from the University of Washington. In 2010, Dr. Montgomery received a scientific achievement award from the Cystic Fibrosis Foundation for his work on medications which collectively have extended the average life span of cystic fibrosis patients by over a decade.
Dr. Montgomery received his B.S. in Chemistry (Magna cum Laude, Outstanding Chemistry Major [Merck Award]), and M.D. (Alpha Omega Alpha Honor Medical Society) from the University of Washington, Seattle. Dr. Montgomery is a board certified internist and pulmonologist. He has served as a board member for ZymoGenetics, and is currently on the board of Alder Pharmaceuticals. In 2012, Dr. Montgomery was honored as one of the top 150 living graduates of the University of Washington College of Arts and Sciences in conjunction with the 150th anniversary of the university.
“As a physician, one learns that prevention is more effective than treatment. Not participating in sports or physical activity can be riskier than playing. At VICIS, both of these thoughts are being addressed by decreasing the risk of injury in sports and encouraging more participation. I am thrilled to be able to help VICIS fulfill its mission.”